These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Plasma proteins and acute phase proteins as tumor markers]. Koch OM; Uhlenbruck G Ric Clin Lab; 1984; 14 Suppl 2():57-65. PubMed ID: 6085184 [No Abstract] [Full Text] [Related]
7. [Paraneoplastic syndrome--an aid in the early detection of malignant tumors?]. Wilmanns W; Possinger K Verh Dtsch Ges Inn Med; 1986; 92():66-76. PubMed ID: 3811567 [No Abstract] [Full Text] [Related]
8. Determination of anti-malignin antibody and malignin in 1,026 cancer patients and controls: relation of antibody to survival. Bogoch S; Bogoch ES; Fager CA; Harris JH; Ambrus JL; Lux WE; Ransohoff JA J Med; 1982; 13(1-2):49-69. PubMed ID: 6750020 [No Abstract] [Full Text] [Related]
9. Overview on new immunologic markers for diagnosis of cancer. Herberman RB Cancer; 1978 Sep; 42(3 Suppl):1595-600. PubMed ID: 361206 [TBL] [Abstract][Full Text] [Related]
10. [New methodological trends--enzyme immunoassay--possibilities for use in tumor diagnosis]. Porstmann B; Porstmann T; Ziegenbein R; Egger E Radiobiol Radiother (Berl); 1983; 24(3):299-312. PubMed ID: 6356214 [No Abstract] [Full Text] [Related]
11. [Immunodiagnosis of malignant diseases. Electrophoresis mobility test in the diagnosis of malignancies]. Douwes FR; Hoffmann W; Mross K; Spellmann HJ Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():793-801. PubMed ID: 77113 [No Abstract] [Full Text] [Related]
12. [Use of chorionic gonadotropin beta subunit determination in the diagnosis of non-trophoblastic malignant neoplasms]. Rodríguez Rodríguez S; Pérez Ramírez A; Medina Malagón L; García Gómez R; Mendoza Rivera R Ginecol Obstet Mex; 1982 Nov; 50(307):293-6. PubMed ID: 7186471 [No Abstract] [Full Text] [Related]
13. [Ectopic production of chorionic gonadotropin by neoplasms]. Wasylewski A; Seweryn J Pol Tyg Lek; 1981 Apr; 36(15):545-7. PubMed ID: 7024945 [No Abstract] [Full Text] [Related]
14. [Paraneoplastic syndromes]. Studer H Schweiz Med Wochenschr; 1973 Oct; 103(41):1429-31. PubMed ID: 4751565 [No Abstract] [Full Text] [Related]
15. [Molecular markers of ovarian carcinoma]. Dobryszycka W Postepy Hig Med Dosw; 2000; 54(4):495-518. PubMed ID: 11016269 [TBL] [Abstract][Full Text] [Related]
16. A serum factor with potential as a tumour marker in malignant lymphoma. Begent RH; Tucker DF; Keen J Br J Cancer; 1980 Mar; 41(3):481-4. PubMed ID: 7387837 [No Abstract] [Full Text] [Related]
17. [Creatine phosphotransferase, B subunit, as a tumor marker. Preliminary results]. Rubial A; Alvarez Moro FJ; Comet R; Bodi R; Lafuerza A; Domenech-Torné FM; Salvador L Rev Esp Oncol; 1984; 31(3):415-20. PubMed ID: 6546170 [TBL] [Abstract][Full Text] [Related]
18. Immunoperoxidase staining in tumor marker distribution studies in cytologic specimen. Coleman DV; To A; Ormerod MG; Dearnaley DP Acta Cytol; 1981; 25(3):205-6. PubMed ID: 7020314 [No Abstract] [Full Text] [Related]
19. Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. Lu H; Goodell V; Disis ML J Proteome Res; 2008 Apr; 7(4):1388-94. PubMed ID: 18311901 [TBL] [Abstract][Full Text] [Related]
20. [Future of malignant stage I melanoma. Immunology and immunotherapy]. Nicolas JF; Berthier O; Trillet-Lenoir V; Claudy A; Revillard JP Ann Dermatol Venereol; 1995; 122(5):324-35. PubMed ID: 8572476 [No Abstract] [Full Text] [Related] [Next] [New Search]